Publications
Search our bibliography using the filters on the right-hand side.
Displaying 151 through 200 of 596 publications.
Skip to main content
Mader G, Mladsi (she/her) D, Zhou X, Sanon M, Wang J, Willey C, Seliger S. Racial differences in mortality rates among elderly Non-ESRD CKD and ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the USRDS. Poster presented at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings; April 2021.
Brodtkorb T-H, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HER2-overexpressed/amplified HR+ breast cancer who initiated neratinib within 1 year of completing trastuzumab in the U.S. Poster presented at the 2021 Virtual AMCP; April 2021. Previously presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS).
Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6
Davis AE, Jiang J, Talbird SE, Turpin R, Mellott CE, Boules M, Wojtowicz AM, Fan T. Pharmacological costs for the treatment of eosinophilic esophagitis in the USA. Poster presented at the 2021 Virtual AMCP; April 2021.
Hicks KA, Ghaswalla P, Carrico J, Anderson S, Novy P, Hogea C, Hayney MS. Estimations of the cost of university-based outbreaks of serogroup B meningococcal disease in the United States. Poster presented at the Pediatric Academic Societies (PAS) 2021 Virtual Meeting; April 2021.
Brockbank J, Krause T, Moss E, Pedersen AM, Morup MF, Ahdesmaki O, Vaughan J, Brodtkorb T-H. Health state utility values in major depressive disorder treated with pharmacological interventions: a systematic literature review. Health Qual Life Outcomes. 2021 Mar 18;19(1):94. doi: 10.1186/s12955-021-01723-x
Appukkuttan S, Farej R, Miles L, Purser M, Wen L. Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2021 Feb;27(2):166-74. doi: 10.18553/jmcp.2020.20330
Anderson S, Talbird S, Fishman J. Cost per responder analysis for pegcetacoplan and eculizumab in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Blood. 2021;138(Suppl 1):4956. doi: 10.1182/blood-2021-153190
Anderson S, Carrico J, Brodtkorb T-H, Lalla D, Brufsky A. Budget impact of introducing neratinib for third-line treatment of HER2+ metastatic breast cancer in the United States. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.
Brodtkorb TH, McDade C, Lalla D, Holmes FA. Cost-effectiveness of neratinib for the extended adjuvant treatment of adult patients with early-stage, HR+, HER2-overexpressed/amplified breast cancer who initiated neratinib within 1 year of completing trastuzumab in the US. Poster presented at the 2020 Virtual San Antonio Breast Cancer (SABCS) Meeting; December 9, 2020.
Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S8-S14. doi: 10.18553/jmcp.2020.26.12-b.s8
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: role of the complement system, pathogenesis, and pathophysiology. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S3-8. doi: 10.18553/jmcp.2020.26.12-b.s3
Bektas M, Copley-Merriman C, Khan S, Sarda SP, Shammo JM. Paroxysmal nocturnal hemoglobinuria: current treatments and unmet needs. J Manag Care Spec Pharm. 2020 Dec;26(12-b Suppl):S14-20. doi: 10.18553/jmcp.2020.26.12-b.s14
Herring W, Gould I, Haines P, Thompson R, Pemberton-Ross P. Predicted delays in dementia onset for an innovative therapy acting on beta-amyloid in patients with mild cognitive impairment due to Alzheimer's disease. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 16, 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Patterson BJ, Herring WL, Van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy LS, Tseng HF. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec;26(12):1567-75. doi: 10.18553/jmcp.2020.20251
Mader G, Purser MF, Mladsi DM, Sanon M, Oberdhan D, Watnick TJ, Seliger SL. Benefit of tolvaptan on time to ESRD for patients with rapidly progressing autosomal dominant polycystic kidney disease (ADPKD): a disease progression model. Poster presented at the 2020 Virtual American Society of Nephrology Kidney Week Conference; October 22, 2020. [abstract] J Am Soc Nephrol. 2020 Oct 22; 31:492.
La EM, Carrico J, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Current estimates of the impact of routine childhood immunizations in reducing vaccine-preventable diseases in the United States. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.
Poirrier J-E, Carrico J, DeMartino JK, Hicks KA, Stoddard JJ, Nagar S, Meyers J. The potential for reducing opioid and analgesic prescriptions via herpes zoster vaccination. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.
Herring W, Benham-Hermetz S, Gustavsson A, Hayek Y. Assessing the value of delayed progression in early Alzheimer's disease: what are the critical issues? Presented at the HTAi 2020 Virtual Annual Meeting; October 13, 2020.
Purser M, Hartley L, Earnshaw S, Bhaila R, Nag A. Economic models used to evaluate the cost-effectiveness of biologic treatments for ulcerative colitis: a systematic literature review. Poster presented at the 2020 Virtual UEG Week Conference; October 11, 2020.
Purser M, Hartley L, Earnshaw S, Bhaila R, Nag A. Systematic literature review to assess the healthcare resource use and costs associated with ulcerative colitis in adults in Europe. Poster presented at the 2020 Virtual UEG Week Conference; October 11, 2020.
Mader G, Mladsi DM, Zhou X, Sanon M, Wang J, Willey CJ, Seliger SL. Mortality risk in elderly ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the United States Renal Data System. Poster presented at the 2020 Virtual American Society of Nephrology Kidney Week Conference; October 22, 2020. [abstract] J Am Soc Nephrol. 2020 Oct; 31:503-4.
Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea CS. Impact of population aging on the burden of vaccine-preventable diseases among older adults in the United States. Hum Vaccin Immunother. 2020 Aug 6;1-12. doi: 10.1080/21645515.2020.1780847
Wilson MR, Wasserman MD, Breton MC, Peloquin F, Earnshaw SR, McDade C, Sings HL, Farkouh RA. Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis. Infect Dis Ther. 2020 Aug;9(2):341-53. doi: 10.1007/s40121-020-00294-6
Bassali J, Gould IG, Kaye JA, Mladsi D, Mehta J. US budget impact model for selinexor in relapsed or refractory multiple myeloma. Clinicoecon Outcomes Res. 2020 Jun 19;12:317-25. doi: 10.2147/CEOR.S251070
Herring WL, Gould IG, Wittrup-Jensen V, Kuti E, Mettam S, Ertle J, Wolowacz S. A conceptual model for the economic evaluation of emerging nonalcoholic steatohepatitis therapies: the impact of treatment efficacy profiles on health outcomes. Poster presented at the 2020 SMDM 18th Biennial European Conference (Conference cancelled); June 16, 2020.
La EM, Talbird SE, Brogan AJ, Davis AE. Budget-impact analysis of ibalizumab in the treatment of US Medicare beneficiaries with multidrug-resistant HIV-1 infection. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S174. doi: 10.1016/j.jval.2020.04.371
Dillon R, Colosia A, Khan S, Masaquel C, McCann E. A systematic literature review of the efficacy and tolerability of polymyxins in resistant Gram-negative infections. Poster presented at the Virtual 2020 30th European Congress of Clinical Microbiology and Infectious Diseases; April 2020.
Wu JJ, Jia X, Zhao Y, Carrico J, Brodtkorb TH, Mendelsohn A, Lowry A, Feldman SR, Armstrong A. Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis. J Dermatolog Trea. 2020 Apr 1;1-8. doi: 10.1080/09546634.2019.1698700
Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Benefit of tolvaptan on time to End-stage Renal Disease (ESRD) for patients with rapidly progressing Autosomal Dominant Polycystic Kidney Disease (ADPKD): a disease progression model. Poster presented at the 2020 National Kidney Foundation Spring Clinical Meeting; March 2020. New Orleans, LA. [abstract] Am J Kidney Dis. 2020 Apr; 75(4):603.
Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. The budget impact of introducing tildrakizumab to a United States health plan for managing moderate-to-severe plaque psoriasis. Pharmacoeconomics. 2020 Mar 26.
Tahami Monfared AA, Stull K, Zhang Q. Staging early Alzheimer's disease using the Alzheimer's Disease Composite Score (ADCOMS). Poster presented at the 12th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting; December 2019. San Diego, CA.
Lucas A, Wilson M, Sings HL, Pugh S, Jones D, Farkouh R, Gessner B, Wasserman M. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. International journal of infectious diseases and therapy. 2019 Dec;4(4):56-66. doi: 10.11648/j.ijidt.20190404.12
Zhang Y, Herring WL, Martin A, Gunsoy N, Zhang W. Development of a novel economic modeling approach for asthma. Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Gallagher J, Russell L, McAlister M, Brockbank J. Impact of gemtuzumab ozogamicin on the Irish healthcare system. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Stull K, Esterberg E, Ajmera M, Candrilli S, Kitt TM, Spalding JR, Patel VP. Use of antifungals and outcomes among inpatients at risk of invasive aspergillosis or mucormycosis in the USA: a retrospective cohort study. Infect Dis Ther. 2019 Dec;8(4):641-55. doi: 10.1007/s40121-019-00267-4
Standaert B, Van Vlaenderen I, Van Bellinghen LA, Talbird SE, Hicks K, Carrico J, Buck PO. Constrained optimization for the selection of influenza vaccines to maximize the population benefit: a demonstration project. Appl Health Econ Health Policy. 2019 Nov 22. doi: 10.1007/s40258-019-00534-y
Brogan AJ, Talbird SE, Davis AE, Wild L, Flanagan D. Is increased screening and early antiretroviral treatment for HIV-1 worth the investment? An analysis of the public health and economic impact of improvement in the UK. HIV Med. 2019 Nov;20(10):668-80. doi: 10.1111/hiv.12788
Wilson M, Moffatt M, Mignon A, McDade C, Wasserman M. Potential public health impact model assessing the switch back to use of the 13-valent infant pneumococcal conjugate vaccine in Belgium on children under 18 years. Poster presented at the World Society for Pediatric Infectious Diseases (WSPID) Conference; November 2019. Manila, Philippines.
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Purser M, Bhaila R, Hartley L, Earnshaw S, Nag A. Economic evaluations of biological treatments for moderate-to-severe Crohn's Disease: findings from a systematic literature review. Poster presented at the 2019 United European Gastroenterology UEG Week; October 23, 2019. Barcelona, Spain. [abstract] United European Gastroenterol J. 2019 Oct; 7:907.
Patterson BJ, Herring W, Van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy L, Tseng H. Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: utilizing real‐world epidemiological data in a budget impact model. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, DC. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S23.
Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, Forsmark A, Vickers AD, Lloyd A. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019 Jun;37(6):845-65. doi: 10.1007/s40273-019-00769-6
Herring W, Rosen B. Economic model for ResVax for maternal vaccination against infant respiratory syncytial virus disease in the United States. Presented at the 2019 Respiratory Syncytial Virus Consortium in Europe; June 2019. Utrecht, The Netherlands.
Talbird SE, La EM, Carrico J, Poston S, Poirrier JE, DeMartino JK, Hogea C. Cost-benefit analysis of vaccination against four preventable diseases in older adults in the United States. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb TH, Mendelsohn AB, Lowry S, Wu JJ, Feldman SR, Armstrong AW. Budget-impact and cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis from a US health plan perspective. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA.
Filonenka A, Law A, Purser M, Mader G, Graham J. Economic burden of unintended pregnancy in the United States. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 20, 2019. New Orleans, LA.
Mader G, Purser M, Mladsi D, Sanon M, Oberdhan D, Watnick T, Seliger S. Modeling disease progression in patients at risk of rapid progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD): using the mayo classification prediction equation. Poster presented at the 2019 National Kidney Foundation Spring Clinical Meeting; May 9, 2019. Boston, MA.
Mauskopf J, Herring W, Zhang Y, Tahami A. The variability in structural assumptions in models estimating the effectiveness of hypothetical disease modifying treatment for Alzheimer's disease. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Supplement 2):S272.